Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease

Date
2020-07-07
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Wiley
Abstract

Objective To determine the inflammatory analytes that predict clinical progression and evaluate their performance against biomarkers of neurodegeneration.

Methods A longitudinal study of MCI‐AD patients in a Discovery cohort over 15 months, with replication in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) MCI cohort over 36 months. Fifty‐three inflammatory analytes were measured in the CSF and plasma with a RBM multiplex analyte platform. Inflammatory analytes that predict clinical progression on Clinical Dementia Rating Scale‐Sum of Boxes (CDR‐SB) and Mini Mental State Exam scores were assessed in multivariate regression models. To provide context, key analyte results in ADNI were compared against biomarkers of neurodegeneration, hippocampal volume, and CSF neurofilament light (NfL), in receiver operating characteristic (ROC) analyses evaluating highest quartile of CDR‐SB change over two years (≥3 points).

Results Cerebrospinal fluid inflammatory analytes in relation to cognitive decline were best described by gene ontology terms, natural killer cell chemotaxis, and endothelial cell apoptotic process and in plasma, extracellular matrix organization, blood coagulation, and fibrin clot formation described the analytes. CSF CCL2 was most robust in predicting rate of cognitive change and analytes that correlated to CCL2 suggest IL‐10 pathway dysregulation. The ROC curves for ≥3 points change in CDR‐SB over 2 years when comparing baseline hippocampal volume, CSF NfL, and CCL2 were not significantly different.

Interpretation Baseline levels of immune cell chemotactic cytokine CCL2 in the CSF and IL‐10 pathway dysregulation impact longitudinal cognitive and functional decline in MCI‐AD. CCL2’s utility appears comparable to biomarkers of neurodegeneration in predicting rapid decline.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Pillai, J. A., Bena, J., Bebek, G., Bekris, L. M., Bonner‐Jackson, A., Kou, L., Pai, A., Sørensen, L., Neilsen, M., Rao, S. M., Chance, M., Lamb, B. T., & Leverenz, J. B. (2020). Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease. Annals of Clinical and Translational Neurology, 7(7), 1225–1239. https://doi.org/10.1002/acn3.51109
ISSN
2328-9503
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Annals of Clinical and Translational Neurology
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}